WebNov 29, 2024 · BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer. ... Low-dose BIVV001 demonstrated an extended half-life of 37.6 hours, compared with a 12.1-hour half-life for rFVIII. Average FVIII activity post-infusion of BIVV001 was … Webof BIVV001, administered in a single dose by intravenous injection in patients with severe hemophilia A. Enrollment in the group that received 25 IU per kilogram of BIVV001 was …
BIVV001: The First Investigational Factor VIII Therapy
WebNov 13, 2024 · Total BIVV001 consumption during perioperative period for major surgery [ Time Frame: baseline to week 52 ] Number of blood component transfusions used during … WebMar 11, 2024 · These findings showed that BIVV001 could provide a high level of sustained factor VIII activity in patients with severe hemophilia A. Overall, single-dose BIVV001 … irthly
BIVV001, a new class of factor VIII replacement for …
What is Altuviiio for hemophilia? Altuviiio (efanesoctocog alfa), previously known as BIVV001, is an approved long-lasting factor VIII (FVIII) replacement therapy for children and adults with hemophilia A.It is indicated as a prophylactic or preventive therapy to lower the frequency of bleeding episodes, and also can … See more Efanesoctocog alfa is based on Fc fusion technology, and is made by adding a region of a blood-clotting protein called von Willebrand factor (VWF) and a polypeptide … See more Sanofi and Sofi announced plans to begin filing applications to regulatory agencies in 2024 requesting that efanesoctocog alfa be approved to treat … See more In preclinical studies, the pharmacological properties of efanesoctocog alfa were found to be similar to those of recombinant FVIII (rFVIII). The … See more An open-label (no placebo group), dose-escalation Phase 1/2a study, called EXTEN-A (NCT03205163), investigated the safety, tolerability, and pharmacokinetics … See more WebSemantic Scholar profile for K. Knockenhauer, with 91 highly influential citations and 40 scientific research papers. WebFeb 18, 2024 · Efanesoctocog alfa, previously known as BIVV001, is an investigational factor VIII replacement therapy that has the potential to transform therapy and provide … portal tchenet